Discontinued — last reported Q4 '25
Vertex Pharmaceuticals Payments for finance leases remained flat by 0.0% to $1.40M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 7.7%, from $1.30M to $1.40M. Over 4 years (FY 2021 to FY 2025), Payments for finance leases shows a downward trend with a -41.8% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase suggests higher reliance on leased assets or expansion of the asset base, while a decrease indicates debt reduction or fewer new lease agreements.
Represents the cash outflows associated with the principal portion of finance lease obligations. These payments reflect...
Standard across capital-intensive industries; peers in semiconductor equipment often report this as part of financing cash flows.
cf_payments_for_finance_leases| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $10.30M | $12.06M | $12.41M | $12.90M | $12.70M | $49.50M | $10.40M | $10.60M | $11.00M | $11.30M | $12.00M | $13.20M | $13.70M | $5.40M | $1.30M | $1.30M | $1.30M | $1.40M | $1.40M |
| QoQ Change | — | +17.0% | +2.9% | +4.0% | -1.6% | +289.8% | -79.0% | +1.9% | +3.8% | +2.7% | +6.2% | +10.0% | +3.8% | -60.6% | -75.9% | +0.0% | +0.0% | +7.7% | +0.0% |
| YoY Change | — | — | — | — | +23.3% | +310.5% | -16.2% | -17.8% | -13.4% | -77.2% | +15.4% | +24.5% | +24.5% | -52.2% | -89.2% | -90.2% | -90.5% | -74.1% | +7.7% |
We use cookies for analytics. See our Privacy and Cookie Policy.